Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
55 pending office actions • 27 art units • 50 examiners • 0 of 55 (0%) have an AI response strategy ready • 74 patents granted in the last 365 days
Takeda Pharmaceutical Company Limited has 54 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 54 pending office actions are reviewed by 50 distinct examiners. The cases are spread across 27 distinct art units, reflecting the technical scope of the company's pharmaceutical research.
TAYLOR, LIA ELAN is the busiest examiner, responsible for 2 busiest examiner pending actions. Despite being the busiest, these 2 busiest examiner pending actions represent only a small portion of the 54 pending office actions. The 50 distinct examiners involved suggest that prosecution strategies must be tailored to a variety of individual examiner preferences.
With 27 distinct art units, the portfolio covers many biotechnological sub-fields. The 54 pending office actions are assigned to 50 distinct examiners. This distribution means that the 2 busiest examiner pending actions held by TAYLOR, LIA ELAN represent a point of examiner overlap in the current data.
Based on the USPTO statutory response window for each pending office action. 18 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 18 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 6 (11%) |
| §103 only | 11 (20%) |
| §112 only | 7 (13%) |
| Double-patenting + other | 14 (25%) |
| Multi-statute (no §101) | 17 (31%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TAYLOR, LIA ELAN | 2 | 64.4% | +29.4% |
| SITTON, JEHANNE SOUAYA | 2 | 53.2% | +48.0% |
| COFFA, SERGIO | 2 | 61.1% | +32.5% |
| KIM, YUNSOO | 2 | 65.9% | +34.3% |
| SIFFORD, JEFFREY MARK | 2 | 55.1% | +32.8% |
| DAVIS, RUTH A | 1 | 60.8% | +31.1% |
| SHIM, DAVID M. | 1 | 58.3% | +58.3% |
| MARTIN, KEVIN STEPHEN | 1 | 77.2% | +23.2% |
| ARIANI, KADE | 1 | 74.9% | +32.4% |
| EISENBERG, REBECCA E | 1 | 81.2% | +12.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17769452 | METHOD FOR EVALUATING DRUG TOXICITY | MARTIN, RACHEL E | 127d overdue |
| 17169835 | SEPARATION OF VWF AND VWF PROPEPTIDE BY CHROMATOGRAPHIC METHODS | STEELE, AMBER D | 89d overdue |
| 17416810 | NOROVIRUS VACCINE FORMULATIONS AND METHODS | SIFFORD, JEFFREY MARK | 46d overdue |
| 18029026 | PARATHYROID GLAND CELLS | BEHARRY, ZANNA MARIA | 24d overdue |
| 17778611 | T-CELL MASTER CELL BANK | ZHU, JIANJIAN | 23d overdue |
| 18266848 | CONDITIONALLY BISPECIFIC BINDING PROTEINS | BUTTICE, AUDREY L | 16d |
| 18952409 | STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONS | DAVIS, RUTH A | — |
| 18850485 | SOLID FORMS OF TYK2 INHIBITORS AND METHODS OF USE | MARTIN, KEVIN STEPHEN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17416810 | NOROVIRUS VACCINE FORMULATIONS AND METHODS | SIFFORD, JEFFREY MARK | 46d overdue |
| 17264720 | FORMULATIONS FOR IMPROVED STABILITY OF RECOMBINANT HUMAN PARATHYROID HORMONE | COFFA, SERGIO | 17d overdue |
| 18537204 | RNA BIOMARKERS FOR HEREDITARY ANGIOEDEMA | SITTON, JEHANNE SOUAYA | 34d |
| 18046450 | FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY | KIM, YUNSOO | 54d |
| 18316988 | TREATMENT OF PATIENTS WITH SEVERE VON WILLEBRAND DISEASE UNDERGOING ELECTIVE SURGERY BY ADMINISTRATION OF RECOMBINANT VWF | COFFA, SERGIO | 55d |
| 18952409 | STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONS | DAVIS, RUTH A | — |
| 18850466 | TYK2 INHIBITORS AND USES THEREOF | SHIM, DAVID M. | — |
| 18850485 | SOLID FORMS OF TYK2 INHIBITORS AND METHODS OF USE | MARTIN, KEVIN STEPHEN | — |
| Art Unit | Apps |
|---|---|
| 1641 | 4 |
| 1658 | 3 |
| 1644 | 3 |
| 1671 | 3 |
| 1627 | 2 |
| 1682 | 2 |
| 1622 | 2 |
| 1631 | 2 |
| 1647 | 2 |
| 1613 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18952409 | STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONS | DAVIS, RUTH A | 1699 | §102§112Other | Non-Final OA | — | Pending | Nov 19, 2024 |
| 18850466 | TYK2 INHIBITORS AND USES THEREOF | SHIM, DAVID M. | — | §103 | Non-Final OA | — | Pending | Sep 24, 2024 |
| 18850485 | SOLID FORMS OF TYK2 INHIBITORS AND METHODS OF USE | MARTIN, KEVIN STEPHEN | — | §103§112 | Non-Final OA | — | Pending | Sep 24, 2024 |
| 18829900 | METHODS AND COMPOSITIONS FOR CNS DELIVERY OF ARYLSULFATASE A | ARIANI, KADE | — | §103§112DP | Non-Final OA | — | Pending | Sep 10, 2024 |
| 18723698 | PARTICLE PREVENTION ADAPTER SYSTEM FOR INJECTION PEN | EISENBERG, REBECCA E | 3781 | §102§103Other | Non-Final OA | — | Pending | Jun 24, 2024 |
| 18710764 | CELL PRODUCTION METHOD | WILSON, MICHAEL C | — | §102§103§112 | Non-Final OA | — | Pending | May 16, 2024 |
| 18662935 | COMBINATIONS AND METHODS FOR SUBCUTANEOUS ADMINISTRATION OF IMMUNE GLOBULIN AND HYALURONIDASE | ORWIG, KEVIN S | 3991 | §102§103§112DPOther | Non-Final OA | — | Pending | May 13, 2024 |
| 18657004 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | KLINKEL, KORTNEY L | 1627 | §101DP | Non-Final OA | — | Pending | May 07, 2024 |
| 18697196 | METHOD FOR MEASURING CELL CONCENTRATION | TAVERNINI, BREANNA MARIE | — | §103§112 | Non-Final OA | — | Pending | Mar 29, 2024 |
| 18695720 | METHOD FOR PRODUCING T CELL | MOORE, JOHN DAVID | — | §101§103§112DP | Non-Final OA | — | Pending | Mar 26, 2024 |
| 18691573 | FACILITATED DELIVERY OF CONCENTRATED ANTIBODY FORMULATIONS USING HYALURONIDASE | HOLLAND, PAUL J | 1656 | §102§112 | Non-Final OA | — | Pending | Mar 13, 2024 |
| 18689723 | INFUSION PUMP | SCHMIDT, EMILY LOUISE | — | §102§112 | Non-Final OA | — | Pending | Mar 06, 2024 |
| 18684541 | SELECTIVE MEASUREMENT OF HUMAN FACTOR VIII | THOMPSON, CURTIS A | — | §102§103§112 | Non-Final OA | — | Pending | Feb 16, 2024 |
| 18292586 | ENGINEERED IMMUNE CELL THAT SPECIFICALLY TARGETS MESOTHELIN AND USES THEREOF | TAYLOR, LIA ELAN | — | §102§103 | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18539876 | METHOD FOR PRODUCING NATURAL KILLER CELLS FROM PLURIPOTENT STEM CELLS | BELYAVSKYI, MICHAIL A | — | §103DP | Non-Final OA | — | Pending | Dec 14, 2023 |
| 18537204 | RNA BIOMARKERS FOR HEREDITARY ANGIOEDEMA | SITTON, JEHANNE SOUAYA | 1682 | §112 | Final Rejection | 34d | Pending | Dec 12, 2023 |
| 18379047 | VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | LAU, JONATHAN S | 1693 | §103Other | Non-Final OA | 9d | Pending | Oct 11, 2023 |
| 18285714 | THERAPEUTIC METHODS USING CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS | TAYLOR, LIA ELAN | 1641 | §102§103§112DP | Non-Final OA | — | Pending | Oct 05, 2023 |
| 18550474 | IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN | DEKARSKE, MADELINE MCGUIRE | 1622 | §103§112Other | Final Rejection | — | Pending | Sep 14, 2023 |
| 18550571 | PLASMA KALLIKREIN INHIBITORS | ROBINSON, MIKHAIL O'DONNEL | 1627 | §112DP | Non-Final OA | 79d overdue | Pending | Sep 14, 2023 |
| 18550306 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | FERGUSON, JALISA HOLMES | 1626 | §112DP | Non-Final OA | — | Pending | Sep 13, 2023 |
| 18546384 | CELL THERAPY COMPOSITIONS AND METHODS FOR MODULATING TGF-B SIGNALING | HOWARD, ZACHARY C | 1674 | §102§112 | Non-Final OA | — | Pending | Aug 14, 2023 |
| 18231982 | FORMULATIONS COMPRISING GLUCOCEREBROSIDASE AND ISOFAGOMINE | CURRENS, GRANT CARSON | 1651 | §103DPOther | Non-Final OA | — | Pending | Aug 09, 2023 |
| 18361790 | METHODS AND COMPOSITIONS FOR CRYOPRESERVATION OF IMMUNE CELLS | HUMPHRIES, NICHOLAS ADAM | 1631 | §103 | Final Rejection | — | Pending | Jul 28, 2023 |
| 18224308 | METHOD AND APPARATUS FOR PROVIDING A PHARMACOKINETIC DRUG DOSING REGIMEN | FONSECA LOPEZ, FRANCINI ALVARENGA | — | §101§103§112DP | Non-Final OA | — | Pending | Jul 20, 2023 |
| 18266848 | CONDITIONALLY BISPECIFIC BINDING PROTEINS | BUTTICE, AUDREY L | 1647 | §103§112Other | Non-Final OA | 16d | Pending | Jun 13, 2023 |
| 18318218 | CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS | STOICA, ELLY GERALD | 1647 | §112 | Non-Final OA | — | Pending | May 16, 2023 |
| 18316988 | TREATMENT OF PATIENTS WITH SEVERE VON WILLEBRAND DISEASE UNDERGOING ELECTIVE SURGERY BY ADMINISTRATION OF RECOMBINANT VWF | COFFA, SERGIO | 1658 | §103DP | Non-Final OA | 55d | Pending | May 12, 2023 |
| 18248604 | DETERMINATION OF CELLULAR KINETICS AND BIODISTRIBUTION FOR CAR-T CELLS | SITTON, JEHANNE SOUAYA | 1682 | §101§103§112 | Non-Final OA | — | Pending | Apr 11, 2023 |
| 18029026 | PARATHYROID GLAND CELLS | BEHARRY, ZANNA MARIA | 1632 | §102§103§112 | Non-Final OA | 24d overdue | Pending | Apr 11, 2023 |
| 18025315 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR | SANCHEZ, JUSTIN CHRISTOPHER | 1622 | §112 | Non-Final OA | 76d | Pending | Mar 08, 2023 |
| 18046450 | FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY | KIM, YUNSOO | 1641 | §103Other | Final Rejection | 54d | Pending | Oct 13, 2022 |
| 17916441 | ADAMTS13 VARIANT, COMPOSITIONS, AND USES THEREOF | ROBINSON, HOPE A | 1652 | §112 | Non-Final OA | 72d overdue | Pending | Sep 30, 2022 |
| 17906433 | IMPLANTABLE CELL CHAMBER DEVICE AND USES THEREOF | BECKHARDT, LYNDSEY MARIE | 1613 | §103 | Final Rejection | 16d overdue | Pending | Sep 15, 2022 |
| 17759992 | TREATMENT OF MENORRHAGIA IN PATIENTS WITH SEVERE VON WILLEBRAND DISEASE BY ADMINISTRATION OF RECOMBINANT VWF | BARSKY, JARED | 1628 | §103§112 | Non-Final OA | — | Pending | Aug 02, 2022 |
| 17778611 | T-CELL MASTER CELL BANK | ZHU, JIANJIAN | 1631 | §103§112Other | Non-Final OA | 23d overdue | Pending | May 20, 2022 |
| 17773467 | METHOD FOR PRODUCING T CELLS | ABBOTT, KODYE LEE | 1634 | §112 | Non-Final OA | — | Pending | Apr 29, 2022 |
| 17769452 | METHOD FOR EVALUATING DRUG TOXICITY | MARTIN, RACHEL E | 1657 | §101§103§112 | Non-Final OA | 127d overdue | Pending | Apr 15, 2022 |
| 17622585 | TRANSFECTION METHOD | ARNOLD, ERNST V | 1613 | §103 | Non-Final OA | — | Pending | Dec 23, 2021 |
| 17622580 | TRANSFECTION METHOD | MEJIAS, SAMANTHA LEE | 1618 | §103DP | Non-Final OA | 15d | Pending | Dec 23, 2021 |
| 17491813 | EVALUATION AND TREATMENT OF BRADYKININ-MEDIATED DISORDERS | PETRASH, HILARY ANN | 1644 | §112 | Final Rejection | 8d | Pending | Oct 01, 2021 |
| 17416859 | T-CELL RECEPTOR MODIFIED OBJECT | GEORGE, DENNIS CHERIAN | 1644 | §103DP | Final Rejection | — | Pending | Jun 21, 2021 |
| 17326884 | RECOMBINANT VIRAL VECTORS AND NUCLEIC ACIDS FOR PRODUCING THE SAME | JOHNSON, ALLISON MARIE | 1638 | §103 | Final Rejection | — | Pending | May 21, 2021 |
| 17279228 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | D' AMBROSIO, THEA | 1654 | §103§112DP | Final Rejection | — | Pending | Mar 24, 2021 |
| 17169835 | SEPARATION OF VWF AND VWF PROPEPTIDE BY CHROMATOGRAPHIC METHODS | STEELE, AMBER D | 1658 | §101§102§103§112DP | Non-Final OA | 89d overdue | Pending | Feb 08, 2021 |
| 17264720 | FORMULATIONS FOR IMPROVED STABILITY OF RECOMBINANT HUMAN PARATHYROID HORMONE | COFFA, SERGIO | 1658 | §103 | Final Rejection | 17d overdue | Pending | Jan 29, 2021 |
| 17263675 | METHOD FOR PRODUCING CD3-POSITIVE CELL | SHUPE, ELIZABETH A | 1643 | §103 | Final Rejection | 19d | Pending | Jan 27, 2021 |
| 16817671 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF FOR TREATING HEREDITARY ANGIOEDEMA ATTACK | KIM, YUNSOO | 1641 | §112Other | Final Rejection | — | Pending | Mar 13, 2020 |
| 16208294 | FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY AND METHODS OF TREATMENT | HADDAD, MAHER M | 1641 | DPOther | Non-Final OA | — | Pending | Dec 03, 2018 |
| 14437902 | METHOD FOR PREPARATION OF A HIGH CONCENTRATION LIQUID FORMULATION OF AN ANTIBODY | JUEDES, AMY E | 1644 | §103DP | Final Rejection | — | Pending | Apr 23, 2015 |
| 18835922 | ZIKA VACCINES AND IMMUNOGENIC COMPOSITIONS, AND METHODS OF USING THE SAME | ZOU, NIANXIANG | — | §102§103§112 | Non-Final OA | — | Pending | Aug 05, 2024 |
| 18687763 | IMMUNOFOCUS ASSAY FOR DETERMINING THE TITER OF DENGUE VIRUSES | BOESEN, AGNIESZKA | — | §103 | Non-Final OA | — | Pending | Feb 28, 2024 |
| 18523331 | LARGE-SCALE FLAVIVIRAL VACCINE PRODUCTION AND MANUFACTURE | FOLEY, SHANON A | 1671 | §103§112DP | Non-Final OA | — | Pending | Nov 29, 2023 |
| 17802443 | METHOD FOR REMOVING HOST CELL DNA FROM VIRUS PREPARATION | SIFFORD, JEFFREY MARK | 1671 | §103 | Non-Final OA | — | Pending | Aug 25, 2022 |
| 17416810 | NOROVIRUS VACCINE FORMULATIONS AND METHODS | SIFFORD, JEFFREY MARK | 1671 | §102§103§112Other | Final Rejection | 46d overdue | Pending | Jun 21, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial